Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2019 Earnings Conference Call Transcript
Nov 06, 2019 • 08:30 am ET
Good day and welcome to the Amneal Pharmaceuticals 3rd Quarter 2019 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Mark Donohue, Vice President, Investor Relations and Corporate Communications. Please go ahead.
Thank you. Good morning everyone and welcome to Amneal's 3rd Quarter 2019 Earnings Call. Earlier this morning we issued a press release reporting our quarterly results. The press release as well as the slides that we presented on this call are available on our website at www.amneal.com. We're conducting a live webcast of this call, a replay of which will also be available on our website after its conclusion. Please note that today's call is copyrighted material of Amneal is not to be rebroadcast without the company's expressed written consent. I'd also like to remind you that during the course of this call, management will make projections or other forward-looking remarks regarding future events or the future financial performance of the company. It's important to note that such statements about estimated or anticipated annual results prospects or other non-historical facts are forward-looking statements and reflect our current perspective of existing trends and information as of to date. Amneal disclaims any intent or obligation to update these forward-looking statements except as expressly required by law. Actual results may differ materially from current expectations and projections depending on a number of factors affecting the Amneal business. These factors are detailed in our periodic public filings with the Securities and Exchange Commission, including but not limited to the Amneal Pharmaceuticals Inc's Form 10-K for the period ended December 31 2018.
Our discussion today also includes certain non-GAAP measures of the by the SEC. Management uses both GAAP financial measures and disclosed non-GAAP financial measures internally to evaluate and manage the company's operations and to better understand its business. Further management believes inclusion of non-GAAP financial measures provide meaningful supplementary information to and facilitates analysis by investors and evaluate the company's financial performance results of operations and trends. A reconciliation of GAAP to non-GAAP measures is available in this morning's press release and the appendix of today's presentation. On the call this morning are Chirag Patel and Chintu Patel, our Co-CEOs, Todd Branning, our Chief Financial Officer. After prepared remarks, we will hold a Q&A session. Also on the call and available for Q&A is Andy Boyer, our Executive Vice President of Commercial Operations Joseph Todisco, Senior Vice President of Specialty Commercial, Pradeep Bhadauria, Chief Scientific Officer, and David Bauchen, our Chief Legal Officer and Corporate Secretary. Our agenda today Chirag and Chintu will begin with a discussion of our strategic direction. Following that, Todd will review detailed financial results. We will have a question and answer session from prepared remarks. With that I'd like to turn the call over to Chirag.
Thank you, Mark. Good morning everyone and thank you for joining us today to review our new 3rd quarter results. When Chintu and I returned as Co-CEOs in August, we promised that we would evaluate